Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 124.70

-0.8%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Getman who wrote (267)	4/26/1997 2:21:00 PM
From: scaram(o)uche	of 961

Paul, while I wouldn't label it "competition", yes, as a friend of mine says, the "entire CMV market is going to hell in a hand basket". It's an unfortunate possibility, but viruses resistant to PIs are likely to emerge. If this happens, it will play into the hands of Gilead and two efforts.... PMPA (i.v. and oral) and GS 930 (i.v. and oral). In the mean time, Vistide will generate limited revenues and contribute markedly to the long-term data concerning the tox of cidofovir. Thus, the current product will back up herpes efforts. I know a whole bunch of investors jumped on GILD after the flu announcement (wise move, IMO), but one really needs to consider GILD a long-term bet or stay away from it. Good luck. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next